SCHEMBL10249153

SCHEMBL10249153

COCCSc1cnccc1-c1nc2cc(C)cnc2n1C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.36
POLB P06746 2/20 0.36
AR P10275 2/20 0.34
AKT1 P31749 3/20 0.34
PDE10A Q9Y233 1/20 0.34
ALDH1A1 P00352 4/20 0.33
HPGD P15428 2/20 0.33
TP53 P04637 1/20 0.33
AKT2 P31751 2/20 0.33
TDP1 Q9NUW8 3/20 0.33
HSD17B10 Q99714 2/20 0.32
ALOX15 P16050 1/20 0.32
PDE2A O00408 1/20 0.32
LMNA P02545 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
MAPT P10636 1/20 0.32
AOC3 Q16853 1/20 0.32
USP2 O75604 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10249014 0.88 PDE10A (0.35) SMN1; SMN2POLBAKT1PDE10AALDH1A1
SCHEMBL10284419 0.87 POLB (0.46) SMN1; SMN2POLBPDE10AALDH1A1HPGD
SCHEMBL10249293 0.87 AKT1 (0.36) SMN1; SMN2POLBAKT1PDE10AAKT2
SCHEMBL10249146 0.86 HASPIN (0.35) SMN1; SMN2POLBAKT1PDE10AAKT2
SCHEMBL10248971 0.85 PDE10A (0.36) SMN1; SMN2POLBAKT1PDE10AALDH1A1
SCHEMBL10252628 0.85 PDE10A (0.35) SMN1; SMN2POLBAKT1PDE10AALDH1A1
SCHEMBL10249155 0.84 HTT (0.37) SMN1; SMN2POLBAKT1PDE10AALDH1A1
SCHEMBL10249152 0.84 SMN1; SMN2 (0.44) SMN1; SMN2POLBARALDH1A1HPGD
SCHEMBL10252611 0.83 PDE10A (0.35) SMN1; SMN2POLBAKT1PDE10AAKT2
SCHEMBL10249098 0.82 POLB (0.41) SMN1; SMN2POLBALDH1A1HPGDTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461181-B2 Fused heterocyclic compound and use thereof SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2013-06-11 US disclosed
US-8273764-B2 Fused heterocyclic compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-09-25 US disclosed
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2012-07-12 US disclosed
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 SMN1; SMN2 1524/4885POLB 4724/4885AR 624/4885
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 SMN1; SMN2 1524/4885POLB 4724/4885AR 624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.